JETEMA Future Growth
Future criteria checks 4/6
JETEMA is forecast to grow earnings and revenue by 20.9% and 30% per annum respectively. EPS is expected to grow by 19.5% per annum. Return on equity is forecast to be 16.5% in 3 years.
Key information
20.9%
Earnings growth rate
19.5%
EPS growth rate
| Pharmaceuticals earnings growth | 33.4% |
| Revenue growth rate | 30.0% |
| Future return on equity | 16.5% |
| Analyst coverage | Low |
| Last updated | 18 Jan 2024 |
Recent future growth updates
Recent updates
JETEMA (KOSDAQ:216080) Is Posting Healthy Earnings, But It Is Not All Good News
Mar 23
Is JETEMA, Co., Ltd.'s (KOSDAQ:216080) Shareholder Ownership Skewed Towards Insiders?
Feb 25JETEMA (KOSDAQ:216080) Is Carrying A Fair Bit Of Debt
Jan 21The JETEMA (KOSDAQ:216080) Share Price Has Gained 110%, So Why Not Pay It Some Attention?
Dec 17
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 106,000 | 19,000 | 25,000 | 29,000 | 1 |
| 12/31/2024 | 71,800 | 3,000 | 4,000 | 8,000 | 1 |
| 12/31/2023 | 58,716 | 13,966 | -328 | 6,883 | N/A |
| 9/30/2023 | 57,603 | -21,990 | -2,303 | 7,252 | N/A |
| 6/30/2023 | 55,439 | -18,144 | 3,690 | 15,477 | N/A |
| 12/31/2022 | 45,994 | 1,455 | -87,555 | 14,176 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A216080's forecast earnings growth (20.9% per year) is above the savings rate (2.4%).
Earnings vs Market: A216080's earnings (20.9% per year) are forecast to grow slower than the KR market (29.6% per year).
High Growth Earnings: A216080's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: A216080's revenue (30% per year) is forecast to grow faster than the KR market (8.7% per year).
High Growth Revenue: A216080's revenue (30% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A216080's Return on Equity is forecast to be low in 3 years time (16.5%).